• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Kyrle's Disease

Article

Extremely itchy, crusting nodules appeared on the arms and legs of a 42-year-old woman who was undergoing renal dialysis.

Extremely itchy, crusting nodules appeared on the arms and legs of a 42-year-old woman who was undergoing renal dialysis. This was Kyrle's disease (hyperkeratosis follicularis et parafollicularis in cutem penetrans), a chronic condition that is most often seen in the setting of renal dialysis but may also occur in conjunction with diabetes mellitus or internal malignancy. Acquired perforating folliculitis/dermatitis has been proposed as a catch-all term for this condition and is accepted by many practitioners as a synonym.

Kyrle's disease usually remits with renal transplant or management of the internal malignancy. It may improve with better diabetic control. Otherwise, it is notoriously difficult to manage. Drs Charles E. Crutchfield III and Eric J. Lewis of Minneapolis offer a clinical pearl: occlude the most troublesome lesions with a thick application of a class 1 corticosteroid, such as halobetasol or clobetasol, under a thin plastic dressing, such as one of the DuoDerm® products (which vary in thickness), for 1 week. In the case of this patient, such treatment was given a few lesions at a time, over a period of several weeks, with successful results.

Related Videos
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Dapagliflozin slows decline of chronic kidney disease
Primary care physicians should prescribe SGLT2 inhibitors
Related Content
© 2024 MJH Life Sciences

All rights reserved.